LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

107.38 0.16

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

107.08

Max

107.49

Pagrindiniai rodikliai

By Trading Economics

Pajamos

15M

-59M

Pardavimai

2.7M

121M

Pelnas, tenkantis vienai akcijai

-1.216

Pelno marža

-48.914

Darbuotojai

712

EBITDA

14M

-57M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+63.74% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-48M

5.4B

Ankstesnė atidarymo kaina

107.22

Ankstesnė uždarymo kaina

107.38

Naujienos nuotaikos

By Acuity

29%

71%

65 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-16 19:39; UTC

Pagrindinės rinkos jėgos

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

2025-05-17 09:30; UTC

Svarbiausios naujienos
Uždarbis

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

2025-05-17 08:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-17 08:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-17 05:30; UTC

Įsigijimai, susijungimai, perėmimai

Tradeweb Is Looking to Come to a Bond Market Near You -- Barrons.com

2025-05-16 23:18; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

2025-05-16 22:30; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- Update

2025-05-16 21:56; UTC

Rinkos pokalbiai

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

2025-05-16 21:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-16 21:54; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- WSJ

2025-05-16 21:22; UTC

Rinkos pokalbiai

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

2025-05-16 21:17; UTC

Rinkos pokalbiai

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

2025-05-16 21:17; UTC

Svarbiausios naujienos

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

2025-05-16 21:05; UTC

Rinkos pokalbiai

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

2025-05-16 20:55; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-16 20:37; UTC

Svarbiausios naujienos

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

2025-05-16 20:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

2025-05-16 20:30; UTC

Įsigijimai, susijungimai, perėmimai

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

2025-05-16 20:18; UTC

Svarbiausios naujienos

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

2025-05-16 20:16; UTC

Svarbiausios naujienos

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

2025-05-16 20:15; UTC

Uždarbis

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

2025-05-16 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: William K. Daniel Joins Board

2025-05-16 20:10; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: Strategic Investment by KKR Completed

2025-05-16 20:05; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 19:38; UTC

Rinkos pokalbiai

Oil Futures Post Second Straight Weekly Gain -- Market Talk

2025-05-16 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2025-05-16 18:51; UTC

Svarbiausios naujienos

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

2025-05-16 18:41; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

63.74% į viršų

12 mėnesių prognozė

Vidutinis 176.07 USD  63.74%

Aukščiausias 210 USD

Žemiausias 148 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

16

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

107.24 / 112.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

65 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.